Xiaolan Shi

Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma

Xiaolan Shi, Lingzhi Yan, Jingjing Shang et al. · American Journal of Hematology · 2022 · 79 citations · Full text

Medicine, Hematology, Oncology +17

Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway

Hua Sui, Shu-Fang Pan, Yu Feng et al. · BMC Complementary and Alternative Medicine · 2014 · 64 citations · Full text

Medicine, Oncology, Pharmacology +17

Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study

Xiaolan Shi, Lingzhi Yan, Jingjing Shang et al. · Blood · 2018 · 59 citations

Life Sciences, Hematology, Immunology +16

HMGB1 was negatively regulated by HSF1 and mediated the TLR4/MyD88/NF-κB signal pathway in asthma

Liqun Shang, Li Wang, Xiaolan Shi et al. · Life Sciences · 2019 · 59 citations

Life Sciences, Health Sciences, Immunology +9

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma

Lingzhi Yan, Su Qu, Jingjing Shang et al. · Cancer Medicine · 2020 · 51 citations · Full text

Medicine, Hematology, Immunology +17